Physician profile
Nicholas Harman
NPI 1952641193
$2,323.36
in general payments reported to CMS, 2019-2025
23 companies · $390 in 2025
The $390 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $452 · 2021: $432 · 2022: $344 · 2023: $170 · 2024: $410 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $970.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $387.89 | 2019-2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $359.72 | 2020-2025 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $310.54 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $222.29 | 2019-2022 | |
| Pfizer INC. | $114.08 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.30 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $91.22 | 2021-2025 | Ozempic, Rybelsus |
| Amgen INC. | $89.87 | 2020-2024 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $81.82 | 2020-2022 | |
| Alnylam Pharmaceuticals INC. | $69.51 | 2021-2025 | Oxlumo, Givlaari |
| Abbvie INC. | $69.21 | 2021-2024 | |
| Amarin Pharma, INC. | $63.94 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.54 | 2019-2023 | Xifaxan |
| Astellas Pharma US INC | $56.18 | 2020-2024 | Veozah |
| Lundbeck LLC | $44.90 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $44.31 | 2021-2025 | Shingrix, Trelegy Ellipta |
| Axsome Therapeutics, INC. | $36.50 | 2024-2025 | Auvelity |
| Dexcom, INC. | $33.65 | 2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $20.30 | 2021 | |
| Xeris Pharmaceuticals, INC. | $18.66 | 2023 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.52 | 2024 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $12.80 | 2022 | |
| Merck Sharp & Dohme LLC | $12.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Harman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.